Business
Odyssey Health, Inc. Secures Exclusive Global Distribution Rights for BreastCheck™ to Drive Recurring Revenue Growth
Odyssey Health, Inc. (OTCQB: ODYY), a medical device company focused on life-saving technologies, today announced the closing of a definitive sub-license agreement granting its wholly-owned subsidiary, Odyssey Medical Devices, Inc., exclusive worldwide marketing and distribution rights for BreastCheck™.
About this update from Odyssey Health Inc.
[{"type":"text","content":"Agreement Positions Company for Near-Term Revenue and Commercial Launch","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"LAS VEGAS, April 22, 2026 /PRNewswire/ -- Odyssey Health, Inc. (OTCQB: ODYY), a medical device company focused on life-saving technologies, today announced the closing of a definitive sub-license agreement granting its wholly-owned subsidiary, Odyssey Medical Devices, Inc., exclusive worldwide marketing and distribution rights for BreastCheck™.","length":346,"tagName":"p"},{"type":"image","alt":"ODDY Logo 2026","displaySize":"","headline":null,"caption":"ODDY Logo 2026","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":172,"url":"https://media.zenfs.com/en/prnewswire.com/65d88fb51bda08036ff2bc76a2785a1d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DlFTc1x1PvDSLfywZ1AdVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMwMw--/https://media.zenfs.com/en/prnewswire.com/65d88fb51bda08036ff2bc76a2785a1d","width":400,"height":172}},"href":"https://mma.prnewswire.com/media/2962757/new_logo_july_12_2022_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This transaction positions Odyssey to enter the global breast cancer screening market, estimated at approximately $26 billion, with a differentiated, non-invasive, at-home screening solution. BreastCheck™ delivers results in approximately 15 minutes and is designed to aid early-stage detection of breast abnormalities, supporting increased accessibility and frequency of screening.","length":382,"tagName":"p"},{"type":"text","content":"While not a replacement for mammography, BreastCheck™ is designed to serve as a first line screening tool, potentially expanding patient engagement and driving recurring usage. BreastCheck™ is registered with the U.S. Food and Drug Administration) and with regulatory authorities in the European Union and the United Kingdom, enabling a broad commercial footprint.","length":364,"tagName":"p"},{"type":"text","content":""With the addition of BreastCheck™, we are advancing our strategic transition toward revenue-generating commercial products with recurring revenue potential," said Michael Redmond, President and CEO of Odyssey. "We believe this agreement provides a clear pathway to near-term revenue, with commercial sales anticipated to commence in the second...